Analyzing gene changes in drug-resistant Multiple Myeloma
Transcriptomics and Epigenetics Analysis for Biomarkers Identification Involved in Drug-resistance Mechanisms of Multiple Myeloma
This study is trying to understand the gene changes that make Multiple Myeloma harder to treat, by looking at patients with different stages of the disease to see what makes some respond to treatment and others not.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Regina Elena Cancer Institute Academic / other |
| Locations | 2 sites (Roma and 1 other locations) |
| Trial ID | NCT05888636 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on understanding the genetic and epigenetic factors contributing to drug resistance in Multiple Myeloma (MM). It will analyze a cohort of patients with conditions ranging from Monoclonal Gammopathy of Undetermined Significance (MGUS) to active MM, utilizing advanced techniques such as ChIP-seq, NGS, and ATAC-seq to characterize transcriptional and epigenetic profiles. The study aims to identify specific miRNA expressions and other genetic markers that differentiate between MM cells that respond to treatment and those that do not.
Who should consider this trial
Good fit: Ideal candidates for this study include patients diagnosed with MGUS, smoldering MM, or active MM.
Not a fit: Patients with other hematological malignancies or those who are not diagnosed with any form of Multiple Myeloma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with Multiple Myeloma by identifying new targets for therapy.
How similar studies have performed: Other studies have shown promise in using transcriptomic and epigenetic analyses to understand drug resistance in various cancers, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: - Compare Transcriptomics and epigenetic profile Exclusion Criteria: * No exclusion criteria
Where this trial is running
Roma and 1 other locations
- Regina elena Cancer Institute — Roma, Italy (Active_not_recruiting)
- "Regina Elena" National Cancer Institute — Rome, Italy (Recruiting)
Study contacts
- Principal investigator: Maurizio Fanciulli, PhD — IRCCS "Regina Elena" National Cancer Institute
- Study coordinator: Maurizio Fanciulli, PhD
- Email: maurizio.fanciulli@ifo.it
- Phone: *39 06 52662800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.